Targeting the vasculature to enhance anti-tumor immunity
Targeting the vasculature to enhance anti-tumor immunity
批准号:
10621205
负责人:
Andrew Carl Dudley
金额:
$38.95万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-09-01 至 2025-06-30
关键词:
AdhesionsAngiogenesis InhibitorsAngiogenic FactorAreaAttentionBiological AssayBlood VesselsBrainBrain NeoplasmsBreast Cancer ModelCD8-Positive T-LymphocytesCancer Cell GrowthCell Adhesion MoleculesCell CommunicationCell LineCell ProliferationCell SurvivalCell divisionCell physiologyCellsCoculture TechniquesComplexCuesCyclic AMP-Dependent Protein KinasesCyclin-Dependent Kinase InhibitorCytotoxic T-LymphocytesDNA MethylationDNA Modification MethylasesDNA deliveryDevelopmentE-SelectinEndothelial CellsEndotheliumEnvironmentEnzymesEpigenetic ProcessExcisionFGF2 geneFibroblast Growth Factor ReceptorsFlow CytometryGatekeepingGene SilencingGenesGeneticGenetically Engineered MouseGoalsGrowthGrowth FactorHeterogeneityHumanImmuneImmune EvasionImmune systemImmunologic SurveillanceImmunosuppressionImmunotherapyImpairmentIn VitroInfiltrationInterferon Type IIInvestmentsLabelLinkLymphocyte DepletionMediatingMetastatic malignant neoplasm to brainMethylationMicrofluidic MicrochipsModelingMorphogenesisMusNeoplasm MetastasisNeoplasms in Vascular TissueNormal tissue morphologyPathway interactionsPenetrationPerfusionPermeabilityPlayPositioning AttributePrimary NeoplasmProliferatingProtein Kinase CResearch PersonnelRoleShapesSmall Interfering RNASolid NeoplasmSpecific qualifier valueStructureT-LymphocyteTNF geneTropismTumor BiologyTumor BurdenTumor ImmunityTyrosine Kinase InhibitorWorkbioluminescence imagingblood vessel developmentcancer cellcancer immunotherapycancer survivalchemokinecombinatorialderepressionimmune cell infiltrateimmune checkpoint blockadeimmunosuppressedimprovedinhibitorinterestloss of functionlymphocyte traffickingmalignant breast neoplasmmethylation patternmonolayermouse modelnanoparticleneoplastic cellneovascularizationrecruitself-renewalsingle-cell RNA sequencingstem cell self renewalstem cellstreatment strategytumortumor growthtumor microenvironmenttumor progressiontumor-immune system interactions
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Tumor-associated endothelial cells (ECs) line the blood vessels that promote the growth and support the
dissemination and survival of cancer cells. The tumor vasculature is also a gatekeeper that controls the
passage of immune cells both into and out of the tumor microenvironment. We recently used single cell RNA
sequencing (sc-RNAseq) to characterize EC heterogeneity in a mammary tumor model; from these studies, we
turned our attention to DNA methyltransferase1 (DNMT1) which has well-defined roles in stem/progenitor cell
self-renewal via it's ability to re-establish patterns of methylation in dividing cells, but no known role in
regulating EC function in tumors. Using mice with conditional deletion of DNMT1 in ECs (DNMT1iECKO mice),
we show inhibition of tumor growth and metastatic seeding and reduced vessel complexity/branching. We
propose these effects are due to a loss of methylation-dependent EC specification required for
neovascularization and are due to de-repression of Th1 chemokines (e.g. Cxcl9/Cxcl10, and Cxcl11) and cell
adhesion molecules (e.g. Vcam1, Icam1/2, and E-selectin) in ECs that recruit and retain cytotoxic T-
lymphocytes to impair tumor growth. In aim 1 we will use DNMT1iECKO mice and vascular-tropic nanoparticles
to determine how targeting DNMT1 regulates EC morphogenesis, perfusion, and permeability during cancer
cell survival. In aim 2 we will use metastasis models to assess how vascular DNMT1 shapes the tumor
immune microenvironment via its ability to regulate cell adhesion molecules (CAMs) and CTL-mobilizing
chemokines in ECs. In aim 3 we will examine mechanisms of immune suppression by a FGF2/DNMT1 axis
that triggers methylation-induced silencing of CAMs and chemokines in tumor-associated ECs. To complete
our goals, we have assembled a team of investigators with expertise in DNA methylation (S. Bhatnager), tumor
immune micro environments (V. Engelhard), and the development of microfluidics devices to study EC-to-T-cell
interactions (R. Kamm). Together, our study characterizes a completely unexplored area; namely, identifying
how methylation-dependent pathways regulate the complex functional diversity, specification, and
immunosuppressive features of tumor-associated ECs.
期刊论文(21)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.2174/2211552811201020133
发表时间:
2012-06-01
期刊:
Current angiogenesis
影响因子:
--
作者:
[Dunleavey JM, Dudley AC]
通讯作者:
Dudley AC
DOI:
10.1007/s10456-023-09876-7
发表时间:
2023-08
期刊:
Angiogenesis
影响因子:
9.8
作者:
[]
通讯作者:
DOI:
10.1158/1078-0432.ccr-14-0493
发表时间:
2014-12-01
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
[Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC]
通讯作者:
Zamboni WC
DOI:
10.1002/stem.583
发表时间:
2011-02
期刊:
STEM CELLS
影响因子:
5.2
作者:
[Melero-Martin, Juan M., Dudley, Andrew C.]
通讯作者:
Dudley, Andrew C.
DOI:
10.1038/srep14257
发表时间:
2015-09-21
期刊:
Scientific reports
影响因子:
4.6
作者:
[Thoppil RJ, Adapala RK, Cappelli HC, Kondeti V, Dudley AC, Gary Meszaros J, Paruchuri S, Thodeti CK]
通讯作者:
Thodeti CK
共 11 条
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
-
批准号:10356164
-
项目类别:
-
资助金额:$56.85万
-
财政年份:2021
-
负责人:Andrew Carl Dudley
-
依托单位:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
-
批准号:10179715
-
项目类别:
-
资助金额:$60.97万
-
财政年份:2021
-
负责人:Andrew Carl Dudley
-
依托单位:
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
-
批准号:10573196
-
项目类别:
-
资助金额:$56.85万
-
财政年份:2021
-
负责人:Andrew Carl Dudley
-
依托单位:
Mechanisms of tumor escape from anti-angiogenic therapy
-
批准号:8693221
-
项目类别:
-
资助金额:$31.28万
-
财政年份:2014
-
负责人:Andrew Carl Dudley
-
依托单位:
Mechanisms of tumor escape from anti-angiogenic therapy
-
批准号:8887312
-
项目类别:
-
资助金额:$31.28万
-
财政年份:2014
-
负责人:Andrew Carl Dudley
-
依托单位:
Targeting the vasculature to enhance anti-tumor immunity
-
批准号:10399410
-
项目类别:
-
资助金额:$35.61万
-
财政年份:2014
-
负责人:Andrew Carl Dudley
-
依托单位:
Targeting the vasculature to enhance anti-tumor immunity
-
批准号:10092966
-
项目类别:
-
资助金额:$36.34万
-
财政年份:2014
-
负责人:Andrew Carl Dudley
-
依托单位:
Tumor endothelial cell abnormalities
-
批准号:8325609
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2009
-
负责人:Andrew Carl Dudley
-
依托单位:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
-
批准号:7708266
-
项目类别:
-
资助金额:$13.07万
-
财政年份:2009
-
负责人:Andrew Carl Dudley
-
依托单位:
Characterizing tumor endothelial cell abnormalities to develop rational anti-angi
-
批准号:8231654
-
项目类别:
-
资助金额:$13.36万
-
财政年份:2009
-
负责人:Andrew Carl Dudley
-
依托单位:
Tumor endothelial cell abnormalities
-
批准号:8312046
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2009
-
负责人:Andrew Carl Dudley
-
依托单位:
Tumor endothelial cell abnormalities
-
批准号:8526412
-
项目类别:
-
资助金额:$23.41万
-
财政年份:2009
-
负责人:Andrew Carl Dudley
-
依托单位:
Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies
-
批准号:10685245
-
项目类别:
-
资助金额:$42.77万
-
财政年份:1976
-
负责人:Andrew Carl Dudley
-
依托单位:
海外基金